vaccines-08-00334.pdf - Article Characterization of...

  • No School
  • AA 1
  • 15

This preview shows page 1 - 2 out of 15 pages.

Article Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study Christel Protiere 1, * , Lisa Fressard 1 , Marion Mora 1 , Laurence Meyer 2 , Marie Pr é au 3 , Marie Suzan-Monti 1 , Jean-Daniel Leli è vre 4 , Olivier Lambotte 5,6,7 , Bruno Spire 1 and the APSEC Study Group 1 Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sant é & Traitement de l’Information M é dicale, 13005 Marseille, France; [email protected] (L.F.); [email protected] (M.M.); [email protected] (M.S.-M.); [email protected] (B.S.) 2 INSERM, U1018, Universit é Paris-Sud 11, AP-HP, H ô pital de Bic ê tre, D é partement D’ é pid é miologie, 94270 Le Kremlin-Bic ê tre, France; [email protected] 3 GRePS, Lyon 2 Universit é , 69676 Bron, France; [email protected] 4 INSERM, U955, Equipe 16, Universit é Paris Est, Facult é de m é decine, Vaccine Research Institute, 94000 Cr é teil, France; [email protected] 5 Assistance Publique-H ô pitaux de Paris, H ô pital Bic ê tre, Service de M é decine Interne et Immunologie Clinique, INSERM, U1184, 94270 Le Kremlin-Bic ê tre, France; [email protected] 6 Immunology of Viral Infections and Autoimmune Diseases, Universit é Paris Sud, UMR 1184, 94270 Le Kremlin-Bic ê tre, France 7 CEA, DSV / iMETI, IDMIT, 92260 Fontenay-aux-Roses, France * Correspondence: [email protected] Received: 13 May 2020; Accepted: 17 June 2020; Published: 23 June 2020 Abstract: HIV cure-related clinical trials (HCRCT) with analytical antiretroviral treatment interruptions (ATIs) have become unavoidable. However, the limited benefits for participants and the risk of HIV transmission during ATI might negatively impact physicians’ motivations to propose HCRCT to patients. Between October 2016 and March 2017, 164 French HIV physicians were asked about their level of agreement with four viewpoints regarding HCRCT. A reluctance score was derived from their answers and factors associated with reluctance identified. Results showed the highest reluctance to propose HCRCT was among physicians with a less research-orientated professional activity, those not informing themselves about cure trials through scientific literature, and those who participated in trials because their department head asked them. Physicians’ perceptions of the impact of HIV on their patients’ lives were also associated with their motivation to propose HCRCT: those who considered that living with HIV means living with a secret were more motivated, while those worrying about the negative impact on person living with HIV’s professional lives were more reluctant. Our study highlighted the need to design a HCRCT that minimizes constraints for participants and for continuous training programs to help physicians keep up-to-date with recent advances in HIV cure research.
Image of page 1
Image of page 2

You've reached the end of your free preview.

Want to read all 15 pages?

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes